Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

An investigational extended-release formulation of minoxidil appears to result in more hair growth in a small phase 2 trial comparing it with immediate-release oral and topical formulations.

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.

Finance is fast becoming one of the most high-impact areas for AI adoption. From anomaly detection to predictive compliance, today’s AI-powered tools help turn complexity into easily digestible data ...

AI shifts from promise to practice when customization becomes routine. That is a positive sign. When technical teams work with data as it is, measure progress with discipline, and focus on workflows ...

We'll compare five of the best IDP platforms available in 2025, covering what they do well, where they may fall short, and ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

The auto industry is flashing warning lights on the state of the U.S. economy. Automakers' profits are getting squeezed by tariffs. A subprime auto lender recently collapsed, and some car retailers ...

Acumatica has announced the general availability of its 2025 R2 ERP Platform. The R2 release features new and updated enhancements that improve usability, ...

Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Ratings for Vertex (NASDAQ: VERX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and ...